The startup specializes in allogeneic cell immunotherapies utilizing gammadelta T-cells to target hematologic malignancies and solid tumors. By harnessing the unique properties of these immune cells, the company aims to provide effective treatment options for patients with various types of cancer.
Funding
Funding not disclosed
Founders
Product
Problem
Conventional CAR-T cell therapies face challenges in manufacturing scalability, high costs, potential safety issues, and limited efficacy against solid tumors. Traditional methods for expanding gamma/delta T-cells (γδ-T cells) are inconsistent and result in exhausted cells, while viral transduction methods for CAR construction can raise safety concerns.
Solution
PhosphoGam is developing non-viral allogeneic CAR-T cell therapies using gamma/delta T-cells (γδ-T cells) to target both hematologic malignancies and solid tumors. Their platform leverages proprietary small molecule expansion agents to produce large quantities of highly active γδ-T cells from healthy donors, ensuring cell fitness and consistent manufacturing. The company's mRNA CAR-γδ-T cell platform offers enhanced safety through non-viral construction and a unique ex vivo durability strategy that eliminates the risk of secondary cancers. PhosphoGam's approach enables redosing, tumor-homing, and controlled therapeutic persistence for improved patient outcomes.
Target Audience
The primary target audience includes patients with hematologic malignancies and solid tumors who can benefit from safer, more effective, and scalable CAR-T cell therapies.
Features
- Proprietary small molecule expansion agents for scalable and consistent γδ-T cell manufacturing
- Non-viral mRNA CAR construction for enhanced safety and rapid R&D cycle times
- Allogeneic application without edits, eliminating the "Allo tax" on manufacturing
- Tumor-homing technology to enhance trafficking of CAR-T cells to the tumor
- Redosing capabilities for sustained therapeutic effect without edits
- High CAR-T cell viability, transfection efficiency, and CAR expression
- Manufacturing scale to treat thousands of patients per year from a single GMP suite